Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yukio Kobayashi, Takahiro Yamauchi, Hitoshi Kiyoi, Toru Sakura, Tomoko Hata, Kiyoshi Ando, Aiko Watabe, Akiko Harada, Tillmann Taube, Yasushi Miyazaki, Tomoki Naoe
Médium: Artigo
Jazyk:angličtina
Vydáno: 2015
On-line přístup:https://doi.org/10.1111/cas.12814
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12814
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!